Carlos Rodriguez-Galindo Discusses Rare Cancer Research
Carlos Rodriguez-Galindo, MD, chair of the Department of Global Pediatric Medicine and director of the International Outreach Program at St. Jude Children’s Research Hospital, and chair of the rare tumor committee at the Children’s Oncology Group, talks about the role rare cancer research has in advancing cancer care as a whole.
Carlos Rodriguez-Galindo, MD, chair of the Department of Global Pediatric Medicine and director of the International Outreach Program at St. Jude Children’s Research Hospital, and chair of the rare tumor committee at the Children’s Oncology Group, talks about the role rare cancer research has in advancing cancer care as a whole.
Rodriguez-Galindo feels that someone with a rare cancer has the same rights as someone with a common cancer, meaning access to research and experts. With pediatric cancers already facing disparities, if researchers want to advance the fight against cancer, it must be done on all fronts. Also, Rodrigues-Galindo says that there is a lot that can be learned from rare cancers to help in this fight.
FDA Approves Inotuzumab Ozogamicin for Pediatric Patients With ALL
March 6th 2024The antibody-drug conjugate inotuzumab ozogamicin was approved by the FDA for the treatment of patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
